Clinical data updates on edwards' transcatheter mitral, tricuspid programs presented at europcr

Irvine, calif., may 18, 2021 /prnewswire/ -- edwards lifesciences (nyse: ew) today announced that clinical results from the company's transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at europcr 2021, demonstrating positive outcomes for patients impacted by mitral or tricuspid heart valve disease.
EW Ratings Summary
EW Quant Ranking